(lp0
S'Antares Pharma Set For Multiple Catalysts In 2017 Seeking Alpha - Apr 4, 2017 As the company fulfills its robust pipeline of FDA approvals over the next 24 months, the remaining nine months of 2017 will likely be action-packed.'
p1
aS'Antares Pharma: Realistic Expectations Seeking Alpha - Feb 1, 2017 This article represents an extension to an SA article published December 30, titled &quot;Antares Pharma: Drug Delivery to Multiple Fronts of Profitability&quot;.'
p2
aS'Antares Pharma: Drug Delivery To Multiple Fronts Of Profitability Seeking Alpha - Dec 30, 2016 Over the last several years, investors in Antares Pharma  have experienced multiple disappointments which prompted many shareholders to exit the shares while remaining holders became increasingly impatient, illustrated in the chart below&nbsp;...'
p3
aS'Antares Pharma Inc. and Nivalis Therapeutics Inc. Show Resiliency as They Snap ... Yahoo Finance - Mar 15, 2017 Antares stock has been on a steady rise for the past year. The company develops and manufactures pressure-assisted injector devices that allow patients to self-inject prescription drugs.'
p4
aS"Antares Pharmaceuticals: The Stock To Buy On EpiPen Issues Seeking Alpha - Aug 28, 2016 Recently, Mylan  has come under a lot of attention for the price of its Epinephrine Auto-Injector EpiPen. EpiPen price raises left many consumers upset and has even attracted attention from presidential candidates.Plastic Cap Is Crux of Mylan Argument Against Teva's EpiPen - BloombergStop blaming Mylan for the skyrocketing prices on EpiPens - The Hill "
p5
aS"Antares Pharma Announces Submission of New Drug Application for Quickshot ... GlobeNewswire  - Dec 21, 2016 EWING, N.J., Dec. 21, 2016  -- Antares Pharma, Inc.  today announced that it had submitted a New Drug Application  to the U.S.Company Hopes to Deliver 'Virtually Painless Treatment Experience' with ... - Monthly Prescribing Reference "
p6
aS'Antares Pharma Announces Completion of the QuickShot Testosterone Clinical Program GlobeNewswire  - Sep 22, 2016 EWING, N.J., Sept. 22, 2016  -- Antares Pharma, Inc.  today announced safety results from the dose-blinded, multiple-dose, concentration-controlled, 26-week phase 3 study of QuickShot Testosterone &nbsp;...'
p7
aS'Does Zero-Debt Really Make Antares Pharma Inc  A Financially Strong Company? Simply Wall St - Mar 6, 2017 Any company, including Antares Pharma Inc  with no debt in its capital structure, would maximize capital returns by having an optimal capital structure, which includes debt.'
p8
aS'Have You Heard About This Generic EpiPen Maker? Benzinga - Aug 24, 2016 Mylan is the maker of a device that provides epinephrine in the event of anaphylaxis - also known as the EpiPen. According to Fortune, Mylan built the EpiPen from a &quot;weakening enterprise&quot; in 2007 to become a &quot;pile of money&quot; segment that reportedly&nbsp;...'
p9
aS'Share Watch: Examining the Levels for Antares Pharma, Inc.  Searcy News - 10 hours ago Tracking shares of Antares Pharma, Inc. , the company has a current EV  of 429394. Enterprise Value measures the total value of a specific company.'
p10
a.